Crisaborole

Crisaborole

SCHEMBL595261

N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Crisaborole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PDE4B known ✓ Q07343 19/20 1.00
PDE4A known ✓ P27815 14/20 1.00
PDE4C known ✓ Q08493 14/20 1.00
PDE4D known ✓ Q08499 14/20 1.00
CHRM1 P11229 1/20 1.00
ADRA1A P35348 1/20 1.00
PDE1A P54750 1/20 1.00
PDE3B Q13370 1/20 1.00
PDE7A Q13946 1/20 1.00
PDE3A Q14432 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Crisaborole SCHEMBL29352751 1.00 PDE4B (1.00) PDE4BPDE4APDE4CPDE4DCHRM1
Crisaborole SCHEMBL5583372 1.00 PDE4B (1.00) PDE4BPDE4APDE4CPDE4DCHRM1
SCHEMBL23513127 0.91 PDE4B (1.00) PDE4BPDE4APDE4CPDE4DCHRM1
SCHEMBL12431101 0.90 PDE4B (0.82) PDE4BPDE4APDE4CPDE4DCHRM1
SCHEMBL2529609 0.89 PDE4B (0.80) PDE4BPDE4APDE4CPDE4DCHRM1
SCHEMBL595831 0.89 PDE4B (0.80) PDE4BPDE4APDE4CPDE4DCHRM1
SCHEMBL5583333 0.89 PDE4B (0.80) PDE4BPDE4APDE4CPDE4DCHRM1
SCHEMBL5583207 0.88 PDE4B (1.00) PDE4BPDE4APDE4CPDE4DCHRM1
SCHEMBL595173 0.88 PDE4B (1.00) PDE4BPDE4APDE4CPDE4DCHRM1
SCHEMBL2527257 0.86 PDE4B (0.75) PDE4BPDE4APDE4CPDE4DCHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240358728-A1 BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, LLC (US) 2024-10-31 US claimed
US-20230008130-A1 BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, INC. (US) 2023-01-12 US claimed
US-11447506-B2 Crystal forms of crisaborole in free form and preparation method and use thereof ANACOR PHARMACEUTICALS, INC. (US) 2022-09-20 US claimed
CN-114053280-A Application of phosphodiesterase inhibitor or pharmaceutical composition thereof in preparation of medicine for treating novel coronavirus pneumonia 南方科技大学 2022-02-18 CN claimed
WO-2022027180-A1 APPLICATION OF PHOSPHODIESTERASE INHIBITOR OR PHARMACEUTICAL COMPOSITION THEREOF IN PREPARATION OF DRUG FOR TREATING NOVEL CORONAVIRUS PNEUMONIA 南方科技大学 2022-02-10 WO claimed
EP-3831389-A1 TOPICAL PHARMACEUTICAL FORMULATIONS COMPRISING CRISABOROLE FOR TREATING INFLAMMATORY-RELATED CONDITIONS Anacor Pharmaceuticals, Inc (US) 2021-06-09 EP claimed
EP-3424932-B1 BORONOPHTHALIDES FOR THERAPEUTIC USE ANACOR PHARMACEUTICALS INC (US) 2021-04-07 EP claimed
US-20210002307-A1 Crystal Forms of Crisaborole In Free Form And Preparation Method And Use Thereof ANACOR PHARMACEUTICALS, INC. (US) 2021-01-07 US claimed
US-20210000847-A1 BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, INC. (US) 2021-01-07 US claimed
EP-3383363-B1 TOPICAL PHARMACEUTICAL FORMULATIONS FOR TREATING INFLAMMATORY-RELATED CONDITIONS ANACOR PHARMACEUTICALS INC (US) 2021-01-06 EP claimed
WO-2017102565-A1 PHARMACEUTICAL COMPOSITION COMPRISING A FULVIC ACID AND AT LEAST ONE BORON-CONTAINING COMPOUND DOBMEYER RITA (CH) 2017-06-22 WO claimed
WO-2017093857-A1 TOPICAL PHARMACEUTICAL FORMULATIONS FOR TREATING INFLAMMATORY-RELATED CONDITIONS ANACOR PHARMACEUTICALS, INC. (US) 2017-06-08 WO claimed
US-20170152273-A1 Topical Pharmaceutical Formulations For Treating Inflammatory-Related Conditions ANACOR PHARMACEUTICALS INC. (US) 2017-06-01 US claimed
US-20150216885-A1 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, LLC 2015-08-06 US claimed
EP-2343304-B1 Biocidal boronophthalide compounds ANACOR PHARMACEUTICALS INC (US) 2015-06-10 EP claimed
US-20130316979-A1 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, INC. (US) 2013-11-28 US claimed
US-8039451-B2 Boron-containing small molecules ANACOR PHARMACEUTICALS, INC. (US) 2011-10-18 US claimed
EP-2343304-A1 Biocidal boronophthalide compounds Anacor Pharmaceuticals, Inc. (US) 2011-07-13 EP claimed
US-20100190748-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2010-07-29 US claimed
US-20070293457-A1 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS ANACOR PHARMACEUTICALS, LLC 2007-12-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230008130-A1 BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS NFKBIA, LITAF, LRBA PDE4B 948/4885PDE4A 1385/4885PDE4C 2189/4885
US-20150216885-A1 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS NFKBIA, LITAF, TNF PDE4B 1058/4885PDE4A 1336/4885PDE4C 2209/4885
US-20240358728-A1 BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS NFKBIA, LITAF, LRBA PDE4B 948/4885PDE4A 1385/4885PDE4C 2189/4885
US-20210002307-A1 Crystal Forms of Crisaborole In Free Form And Preparation Method And Use Thereof FGB, CSTB, UGT2B17 PDE4B 1568/4885PDE4A 2561/4885PDE4C 1759/4885
US-20070293457-A1 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS NFKBIA, LITAF, TNF PDE4B 1058/4885PDE4A 1336/4885PDE4C 2209/4885
US-11447506-B2 Crystal forms of crisaborole in free form and preparation method and use thereof FGB, CSTB, UGT2B17 PDE4B 1568/4885PDE4A 2561/4885PDE4C 1759/4885
US-20130316979-A1 BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS NFKBIA, LITAF, TNF PDE4B 1058/4885PDE4A 1336/4885PDE4C 2209/4885
US-20210000847-A1 BORON CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS NFKBIA, LITAF, LRBA PDE4B 948/4885PDE4A 1385/4885PDE4C 2189/4885
US-20170152273-A1 Topical Pharmaceutical Formulations For Treating Inflammatory-Related Conditions TSLP, ASAH2, CYSLTR2 PDE4B 115/4885PDE4A 99/4885PDE4C 133/4885
US-20100190748-A1 BORON-CONTAINING SMALL MOLECULES ETF1, POLR1C, DPM1 PDE4B 4444/4885PDE4A 4397/4885PDE4C 4585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.